Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 4

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 4
---
. Those challenges include slowing                           
 net sales growth and increased competition. Broadwood underestimates the impact of these challenges and the risks they pose to value. |

| • |     | STAAR’s leading EVO ICL is vulnerable because of new and emerging competitors, which will pressure growth 
 and pricing.                                                                                              |

| 3. | Broadwood allegation: STAAR’s “Newfound Strategic Pessimism is an Abrupt About Face” |

| • |     | STAAR Response – Broadwood is taking management’s historical remarks out of context |

| • |     | Management continues to expect that “better days are ahead.” Net sales were down by more than 50% in                                                                             
 the first half of 2025. STAAR expects to return to growth and therefore “better days are ahead,” but that does not mean expected future growth will be as robust as in the past. |

| • |     | Management continues to believe that “we’ve substantially mitigated the tariff risk because                                                                                   
 we’ve got inventory in market that is going to get us through the end of this year, early next (year).” What happens beyond “early next (year)” is more difficult to predict. |

| • |     | Management commentary that “we operate in a very large and growing market, so we will generally enjoy                                                                                                                                   
 tailwinds” was and continues to be a valid expectation. Management projections for 10% net sales growth from 2026 to 2030 support a “tailwind,” but this does not suggest STAAR will revert to its 25% historical growth rate from 2020 
 to 2023.                                                                                                                                                                                                                                |

| • |     | Management commentary that it is “very confident in the long run of the business” was and continues                                                                                                                       
 to be a reasonable expectation, which is why management projected 10% net sales growth from 2026 to 2030. At the same time, it is impossible to ignore the challenges that have decreased net sales each year since 2023. |

Broadwood Allegation of “Wrong Price”

| 1. | Broadwood allegation: “Alcon offered much more for STAAR (less than a year ago)” and 
 “STAAR’s long-term prospects have materially changed since then”                     |

| • |     | STAAR Response – Alcon withdrew its October 2024 offer after conducting due diligence, and 
 STAAR’s long-term prospects are more challenged today than they were a year ago            |

|